

Impact of Thrombopoietin Receptor Agonist Treatment and Adherence in Patients with Primary Chronic Immune Thrombocytopenia: Results of an International Cross-sectional Survey

J. J. Zwaginga,¹ S. Nagalla,² M. Linden,³ M. Lindberg,⁴ C. Kruse,⁵ M. Morgan,⁶ D. Decise,⁷ M. Putnik,⁷ C. Rich⁷

¹Leiden University Medical Center, Leiden, The Netherlands; ²Miami Cancer Institute, Miami, FL, USA; ³ITP-foreningen, 1634 Gamle Fredrikstad, Norway; ⁴ITP Suomi, Ylivieska, Finland; ⁵Platelet Disorder Support Association, Cleveland, OH, USA; ⁶ITP Support Association, Bolnhurst, UK; ⁷Sobi, Stockholm, Sweden

CONCLUSIONS

- This real-world international survey showed that people living with ITP may experience a negative impact on their daily activities and mental health from their condition
- Treatment with some TPO-RAs may also impair specific activities, likely influenced by administration route and dietary restriction

INTRODUCTION

- The symptoms of immune thrombocytopenia (ITP) may substantially impair patient health-related quality of life (HRQoL), including energy/fatigue, physical functioning, daily activities and mental health¹⁻³
- Treatment for people with primary ITP aims to minimise the risk of severe bleeding and optimise HRQoL⁴
- Following first-line oral corticosteroids or intravenous immunoglobulin, three thrombopoietin receptor agonists (TPO-RAs) are currently available: ⁴ romiplostim (ROMI), eltrombopag (ELT) and avatrombopag (AVA), which have different administration modalities
- Studies of patients' perspectives on daily life relating to the administration and adherence of these treatments are limited

OBJECTIVE

- To evaluate the understanding of, and adherence to TPO-RA treatment instructions by people with ITP, and to determine the impact of ITP and TPO-RAs on their daily lives

METHODS

- A cross-sectional, self-administered, online survey conducted from September 2023 to April 2024
- Eligible by people with ITP were aged ≥18 years, had a primary chronic ITP diagnosis and were prescribed a TPO-RA in the last 12 months and for ≥3 months
- Respondents were recruited voluntarily by patient organisations in 6 countries via direct mail, email, and/or online platforms

RESULTS

Baseline characteristics

- In total, 221 respondents completed the survey. Mean (standard deviation [SD]) age was 57.4 (15.5) years, most were female (69%) and mean (SD) time since ITP diagnosis to survey completion was 10.7 (10.6) years (**Table 1**)
- Respondents were from the Netherlands (n=77; 35%), the USA (n=72; 33%), the UK (n=53; 24%), Norway (n=11; 5%), Finland (n=7; 3%) and Germany (n=1; <1%)
- Respondents were currently (n=204)/most recently (n=17) treated with ELT (n=118; 53%), ROMI (n=65; 29%) or AVA (n=38; 17%)

Table 1. Baseline demographics and treatment status

Characteristic	ROMI (n=65)	ELT (n=118)	AVA (n=38)	Total (N=221)
Age, years, mean (SD)	58.9 (14.7)	56.3 (15.7)	58.2 (16.6)	57.4 (15.5)
Female, n (%)	45 (69.2)	81 (68.6) ^a	27 (71.1)	153 (69.2) ^a
Time since ITP diagnosis, years, mean (SD)	10.4 (10.4)	10.6 (10.8)	11.4 (11.0)	10.7 (10.6)
Currently using the indicated TPO-RA, n (%)	61 (93.8)	109 (92.4)	34 (89.5)	204 (92.3)
Recently used the indicated TPO-RA, n (%)	4 (6.2)	9 (7.6)	4 (10.5)	17 (7.7)


^aExcludes 1 (0.5%) patient who preferred not to answer

AVA, avatrombopag; ELT, eltrombopag; ITP, immune thrombocytopenia; ROMI, romiplostim; SD, standard deviation; TPO-RA, thrombopoietin receptor agonist

TPO-RA administration: instructions, education and adherence

- Most respondents (95%) received instructions on how to take their TPO-RA and over one-third (37%) were given ≥5 specific instructions (ELT 58%; AVA 24%; ROMI 9%). Taking treatment at the same time each day/week was the most common instruction (ELT 86%; AVA 84%; ROMI 68%) (**Figure 1**)
- ELT-treated respondents were given the most instructions about food: timing of medication relative to meals (72%), meals relative to medication (65%), and the restriction (44%) or avoidance (69%) of certain foods (**Figure 1**)
- Nearly one-third (32%) of ELT-treated respondents ate when/what they wanted at times despite these instructions, and 64% of this treatment group would prefer to have a TPO-RA with no food/drink restrictions

Figure 1. Specific instructions respondents reported for taking TPO-RA medication



N=221 (ROMI, n=65; ELT, n=118; AVA, n=38)

^aProportion of respondents per treatment who found it important or very important to follow each instruction category
AVA, avatrombopag; ELT, eltrombopag; ROMI, romiplostim; TPO-RA, thrombopoietin receptor agonist


Impact of ITP on daily life/mental health

- Compared to before ITP diagnosis, living with ITP was reported to negatively impact ≥1 daily activity or mental health in 89% of respondents, most commonly travelling (for pleasure [69%]), mental health (66%) and exercise/sport (62%); eating habits (32%) and commuting (to school or work [29%]) appeared to be least affected by ITP diagnosis

Impact of TPO-RA medication on daily life/mental health

- Most respondents reported either no impact or an improvement in ≥1 daily activity or mental health after TPO-RA treatment initiation (**Figure 2**). However, all individual domains were reported to be negatively impacted to some extent by treatment with TPO-RAs; travelling (for pleasure) was most impacted (ROMI 62%, AVA 37%, ELT 24%), while eating habits, sleeping, exercise/sport and mental health were also impacted in ≥30% of respondents

Figure 2. Daily activity/mental health domains affected by ≥1 TPO-RA treatment




N=221 (ROMI, n=65; ELT, n=118; AVA, n=38)

AVA, avatrombopag; ELT, eltrombopag; ROMI, romiplostim; TPO-RA, thrombopoietin receptor agonist

- The majority of respondents who had eating habits affected to some extent by TPO-RAs were receiving ELT (n=47/66), with the greatest impact on when (70%) and what (74%) they eat/ate (**Figure 3**)

Figure 3. Impact of TPO-RA medication on eating habits



N=66 (ROMI, n=11; ELT, n=47; AVA, n=8)

AVA, avatrombopag; ELT, eltrombopag; ROMI, romiplostim; TPO-RA, thrombopoietin receptor agonist

References

1. Cooper N, et al. *Am J Hematol*. 2021;96:199–207; 2. Efficace F, et al. *Am J Hematol*. 2016;91:995–1001; 3. Rovó A, et al. *PLoS One*. 2022;17:e0267342; 4. Provan D, et al. *Blood Adv*. 2019;3:3780–17.

Acknowledgements

The authors would like to thank the participants and patient organisations, including Mieke Budel and Ineke Steetskamp from ITP Patiëntenvereniging Nederland (s-Hertogenbosch, The Netherlands) who contributed to this survey. The poster was created by the authors in accordance with Good Publication Practice (GPP) 2022 guidelines (<https://www.ismpp.org/gpp-2022>). Medical writing, funded by Sobi, was provided by Tyrone Daniel of Genesis Medical Writing Ltd (Manchester, UK). Sobi reviewed and provided feedback on the poster. The authors had full editorial control of the poster and provided their final approval of all content.

Disclosures

JJZ: consultancy fees and travel reimbursement (Sanofi, Sobi), consultancy fees (Amgen). **SN**: none. **M Linden**: consultancy fees (Novartis, Sobi). **M Lindberg** (ITP Suomi): grants (Sobi) and honoraria (Novartis). **CK** (Platelet Disorder Support Association): grants and sponsorship (Amgen, Argex, CSL Behring, Novartis, Rigol, Sanofi, Sobi). **MM** (ITP Support Association): grants and sponsorship (Amgen, Argex, Novartis, Sanofi, Sobi, Grifols). **DD**: employee (Sobi). **MP**: employee (Sobi). **CR**: employee (Sobi).